2,3-bis(4-hydroxyphenyl)-propionitrile has been researched along with rivaroxaban in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dolkart, O; Gigi, R; Katzburg, S; Salai, M; Sharon, O; Somjen, D; Stern, N | 1 |
| Dolkart, O; Katzburg, S; Maman, E; Salai, M; Sharfman, ZT; Sharon, O; Somjen, D; Stern, N | 1 |
2 other study(ies) available for 2,3-bis(4-hydroxyphenyl)-propionitrile and rivaroxaban
| Article | Year |
|---|---|
Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonal-induced physiological modulations in human female osteoblastic cell line SaSO2.
Topics: Alkaline Phosphatase; Anticoagulants; Cell Line; Cell Proliferation; Creatine Kinase; DNA; Enzyme Activation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Factor Xa; Factor Xa Inhibitors; Female; Genistein; Ginsenosides; Humans; Isoflavones; Morpholines; Nitriles; Osteoblasts; Osteogenesis; Parathyroid Hormone; Rivaroxaban; RNA, Messenger; Sapogenins; Thiophenes; Vitamin D | 2013 |
Rivaroxaban significantly inhibits the stimulatory effects of bone-modulating hormones: In vitro study of primary female osteoblasts.
Topics: Adult; Cells, Cultured; Drug Antagonism; Estradiol; Female; Ginsenosides; Humans; Middle Aged; Nitriles; Osteoblasts; Postmenopause; Premenopause; Rivaroxaban; Sapogenins | 2017 |